Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy.

Wei, Shanshan; Hu, Wenwei; Feng, Jun; Geng, Yiting

Wei, Shanshan; Hu, Wenwei; Feng, Jun; Geng, Yiting.

Wei S; Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, Jiangsu, China.
Hu W; Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, Jiangsu, China.
Feng J; Jiangsu Engineering Research Center for Tumor Immunotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Geng Y; Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, Jiangsu, China.

Cell Commun Signal ; 20(1): 150, 2022 09 21.

Article en En | MEDLINE | ID: mdl-36131281

Asunto(s)

Antineoplásicos; Neoplasias Colorrectales; MicroARNs; ARN Largo no Codificante; Anticuerpos Monoclonales/uso terapéutico; Antineoplásicos/uso terapéutico; Cetuximab/genética; Cetuximab/uso terapéutico; Neoplasias Colorrectales/tratamiento farmacológico; Neoplasias Colorrectales/genética; Neoplasias Colorrectales/patología; Receptores ErbB/genética; Receptores ErbB/metabolismo; Humanos; MicroARNs/genética; Mutación; Panitumumab/uso terapéutico; Proteínas Proto-Oncogénicas B-raf/genética; ARN Circular; ARN no Traducido/genética

Palabras clave

Anti-EGFR monoclonal antibody; Colorectal cancer; Resistance; cicrRNA; lncRNA; miRNA; ncRNA

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / MicroARNs / ARN Largo no Codificante / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google